1338247-35-0
1338247-35-0 結(jié)構(gòu)式
基本信息
BMS-5游離態(tài)
CS-2190
BMS 5
BMS5
BMS-5 ≥95%
BMS-5， LIMKI-3
LIMKI-3
BMS5
BMS 5
LIMKI3
LIMKI 3
N-(5-(1-(2,6-dichlorophenyl)-3-(difluoroMethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyraMide
N-[5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methylpropanamide
Propanamide, N-[5-[1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methyl-
N-{5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]- 1,3-thiazol-2-yl}-2-methylpropanamide
物理化學性質(zhì)
Ethanol:3.0(Max Conc. mg/mL);6.96(Max Conc. mM)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | S0185 | BMS-5 BMS-5 | 1338247-35-0 | 5mg | 857.46元 |
| 2024/11/08 | S0185 | BMS-5 BMS-5 | 1338247-35-0 | 25mg | 1775.47元 |
| 2024/11/08 | S0185 | BMS-5 | 1338247-35-0 | 100mg | 6855.74元 |
常見問題列表
| Target | Value |
|
LIMK1
(Cell-free assay) | 7 nM |
|
LIMK2
(Cell-free assay) | 8 nM |
BMS-5 (LIMKi 3) inhibits cofilin-Ser3 phosphorylation in a dose-dependent manner in Nf2 ΔEx2 mouse Schwann cells (MSCs) with an IC 50 of ~2 μM. BMS-5 (LIMKi 3) reduces Nf2 ΔEx2 MSC viability in a dose-dependent manner with an IC 50 of 3.9 μM, but does not significantly reduce the viability of control Nf2 flox2/flox2 MSCs at equivalent BMS-5 concentrations. At 10 μM BMS-5, Nf2 ΔEx2 MSC viability is 40% compared to 83% for controls.
BMS-5 (LIMKi 3) (20 or 200 μM/side) is bilaterally infused into the hippocampus of rats immediately after contextual fear conditioning training. Rats are tested for memory consolidation 48 h after fear conditioning. Post hoc analysis shows that the group treated with 200 μM BMS-5 express lower freezing levels compared to the 20 μM and vehicle groups (P<0.01).